On March 21, 2025, Cyclacel Pharmaceuticals entered into a Securities Purchase Agreement to sell 1,000,000 shares of Series E Convertible Preferred Stock at $1.00 per share, raising $1 million for corporate purposes. The shares are convertible into c...